CA 88

Drug Profile

CA 88

Alternative Names: CA-88

Latest Information Update: 28 Jan 2015

Price : $50

At a glance

  • Originator Medigreen Biotechnology Corporation
  • Class Chemoprotectants; Radioprotectives
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chemotherapy-induced damage; Radiation injuries

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 27 Jan 2015 Discontinued - Phase-I for Chemotherapy induced damage (Prevention) in Taiwan (PO)
  • 20 Jul 2007 Phase-I clinical trials in Chemotherapy induced damage (Prevention)/Chemoprotection in Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top